The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC).
M. G. Vigano'
No relevant relationships to disclose
R. Cavina
No relevant relationships to disclose
S. Novello
No relevant relationships to disclose
F. Grossi
No relevant relationships to disclose
A. Santoro
No relevant relationships to disclose
V. Gregorc
No relevant relationships to disclose
G. Scagliotti
No relevant relationships to disclose
I. M. Garassino
No relevant relationships to disclose
G. Rossoni
No relevant relationships to disclose
M. G. Levra
No relevant relationships to disclose
C. Genova
No relevant relationships to disclose
F. Caligaris-Cappio
No relevant relationships to disclose
A. Lambiase
Employment or Leadership Position - MolMed S.p.A.
C. Bordignon
Employment or Leadership Position - MolMed S.p.A.